EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ViewRay's enterprise value is $3.8 Mil.
ViewRay's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-99.2 Mil. Therefore, ViewRay's EV-to-EBITDA for today is -0.04.
The historical rank and industry rank for ViewRay's EV-to-EBITDA or its related term are showing as below:
VRAYQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.04 Med: 0 Max: 0
Current: -0.04
VRAYQ's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 14.89
vs VRAYQ: -0.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), ViewRay's stock price is $1.0E-5.
ViewRay's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.600. Therefore, ViewRay's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ViewRay EV-to-EBITDA Historical Data
The historical data trend for ViewRay's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ViewRay's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViewRay EV-to-EBITDA Distribution
For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ViewRay's EV-to-EBITDA falls into.
ViewRay EV-to-EBITDA Calculation
ViewRay's EV-to-EBITDA for today is calculated as:
ViewRay's current Enterprise Value is $3.8 Mil.
ViewRay's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViewRay (OTCPK:VRAYQ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ViewRay's share price for today is $1.0E-5.
ViewRay's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ViewRay's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRAYQ has been successfully added to your 